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Introduction
The human epidermal growth factor receptor 2 (HER2) gene has emerged as a very important 
predictor of outcome among patients having invasive breast cancers; its amplification 
is associated with more aggressive disease and a worse prognosis.1,2 HER2 positivity is 
also associated with relative resistance to endocrine therapies3 and non-anthracycline, 
non-taxane containing chemotherapy regimens.4 Most importantly, therapies, such as 
trastuzumab (Herceptin) targeting the HER2 oncoproteins, have recently been established 
as the standard component in the treatment of HER2 overexpressed breast cancers, in 
both adjuvant and metastatic settings.5-7 Accordingly, starting from 2005, HER2 status has 
been incorporated into the risk allocation of the St Gallen consensus to guide the use of 
systemic adjuvant therapies.8
 In Hong Kong, since the late 1990s HER2 testing has been routinely performed for all 
	 Objectives	 To	evaluate	 the	prevalence	of	human	epidermal	growth	 factor	
receptor	2	(HER2)	gene	overexpression	in	breast	cancer	patients	
encountered	in	Hong	Kong	and	the	concordance	of	HER2	findings	
from	 primary	 immunohistochemistry	 assays	 and	 confirmatory	
in-situ	hybridisation	assays.
	 Design	 Retrospective	study.
	 Setting	 Department	of	Clinical	Oncology	 in	a	public	hospital	 in	Hong	
Kong.
	 Patients	 All	patient	referrals	between	July	2006	and	June	2007	with	newly	
diagnosed	 invasive	 breast	 cancer	 (for	 prevalence	 evaluation),	
and	 all	 patients	 treated	 at	 our	 unit	 with	 confirmatory	 in-situ	
hybridisation	 tests	 performed	 within	 the	 study	 period	 (for	
concordance	evaluation).
	 Results	 There	 were	 272	 consecutive	 breast	 cancer	 patients	 eligible	
for	 prevalence	 evaluation.	 The	 distribution	 for	 immunohisto-
chemistry	staining	in	249	cases	for	scores	0,	1+,	2+,	and	3+	were	
99	(40%),	40	(16%),	58	(23%),	and	52	(21%)	respectively.	In	the	
remaining	23	patients,	four	and	19	breast	cancers	were	unscored	
and	 reported	 by	 immunohistochemistry	 to	 be	 HER2-positive	
and	 -negative,	 respectively.	 The	 overall	 HER2	 overexpression	
rate	(3+	or	reported	as	positive)	was	21%.	HER2	overexpression	
was	 associated	with	 grade	 3	 histology	 (P<0.001)	 and	 negative	
hormonal	 receptor	 status	 (P<0.001).	 However,	 it	 was	 not	
associated	 with	 age	 (P=0.525),	 T-classification	 (P=0.740),	 N-
classification	 (P=0.691),	 nor	 group	 stages	 (P=0.433).	Of	 the	 37	
patients	with	confirmatory	in-situ	hybridisation	tests	performed,	
10	 (71%)	of	14	with	 immunohistochemistry	 staining	of	3+	and	
1	 (4%)	 of	 23	with	 immunohistochemistry	 staining	 of	 2+	were	
found	to	have	HER2	gene	amplification.
	 Conclusions	 More	 than	 25%	 of	 HER2	 overexpression	 identified	 by	
immunohistochemistry	 assays	 in	 this	Hong	Kong	 cohort	 could	
not	 be	 verified	 by	 confirmatory	 in-situ	 hybridisation	 assays.	
Compliance	with	 the	 latest	guidelines	 for	HER2	 testing	 should	
improve	the	future	accuracy	and	concordance.
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newly diagnosed invasive breast cancers. Although 
in-situ hybridisation (ISH) assay (for HER2 gene 
amplification) is often considered the more desirable 
method of testing for it, the immunohistochemistry 
(IHC) assay (for HER2 protein overexpression) is 
cheaper, more widely available, and has long been 
the primary screening test in all laboratories. In-situ 
hybridisation tests are often reserved for equivocal 
cases only, but are not currently available in public 
hospitals. Despite the critical importance of HER2 
status in prognosis and treatment decisions, the 
accuracy of the HER2 test has recently become a 
matter of much concern.9-11 Because of the expense 
and potential life-threatening cardiotoxicity of anti-
HER2 therapies,12,13 the importance of accurate HER2 
testing cannot be overemphasised.
 Our study therefore aimed to assess the 
prevalence of HER2 overexpression among patients 
with invasive breast cancers in Hong Kong, and 
evaluate how well the HER2 status determined by 
IHC and the confirmatory ISH assay agreed.
Patients and methods
To assess the prevalence of HER2 overexpression, 
we retrospectively analysed the records of all newly 
diagnosed female breast cancer patients referred to 
the Department of Clinical Oncology, Pamela Youde 
Nethersole Eastern Hospital, Hong Kong between 
the period July 2006 and June 2007. Patients with pure 
in-situ carcinomas or inadequate tissue diagnoses 
were excluded from analysis. Patients presenting 
with metastatic disease were included so as to avoid 
selection bias.
 For evaluation of concordance between IHC 
and ISH results, findings from all ISH tests performed 
within the study period were compared against the 
findings of primary IHC testing. Patients, who first 
presented before the study period, were included 
as long as they had confirmatory ISH tests within the 
study period, so that they could be considered for 
target therapies in either the metastatic or adjuvant 
setting.
Immunohistochemistry assay
Various commercially available anti-HER2 antibodies 
(eg CB11 monoclonal antibodies, Novocastra 
Laboratories, Newcastle-on-Tyne, UK) were used in 
different local laboratories to detect HER2 protein 
in IHC assays. The stained slides were scored on a 0 
to 3+ scale—0 was given if there was no membrane 
staining or if staining was present in less than 10% 
of tumour cells; 1+ for faint, or barely perceptible 
membrane staining in more than 10% of cells with 
stain involving only part of the cell membrane; 2+ 
for weak-to-moderate complete staining in more 
than 10% of tumour cells; and 3+ for strong complete 
membrane staining in more than 10% of tumour 
cells. Respective scores of 0 and 1+ were considered 
HER2-negative, 2+ as HER2 equivocal, and 3+ as HER2-
positive.
In-situ hybridisation assay
Although the ISH assay is not yet available in public 
laboratories, it can be performed in some private or 
university laboratories, mainly for confirmation of 
HER2 status in patients with IHC scores of 2+ or 3+. 
There were two main types of ISH tests used in our 
patients; fluorescence in-situ hybridisation (FISH) and 
chromogenic in-situ hybridisation (CISH). The latter 
tests were performed in some private laboratories for 
IHC 2+ patients before referral. For IHC 3+ patients, 
confirmatory ISH tests were considered unnecessary, 
even in laboratories with ISH facilities. However, as 
we preferred to have confirmatory ISH tests for 
IHC 3+ patients before starting them on anti-HER2 
therapy, we arranged FISH tests in the University of 
Hong Kong for those who agreed to self-finance the 
confirmatory tests.
		#		Yau	et	al	#
132	 Hong	Kong	Med	J		Vol	14	No	2	#	April	2008	#		www.hkmj.org
 Fluorescence in-situ hybridisation tests were 
performed in the Molecular Pathology Laboratory, 
Department of Pathology, University of Hong Kong. 
It involved using the Food and Drug Administration 
(FDA)–approved PathVysion HER-2 DNA Probe Kit 
(Abbott Molecular Inc, Des Plaines [IL], US) for 
dual signal evaluation. HER2 gene amplification was 
defined as HER2 probe/control probe ratio of 2.2 or 
more for at least 40 nuclei of invasive cancer cells. 
An additional 20 nuclei were counted, whenever a 
borderline ratio (1.8-2.2) was initially found.
 Chromogenic in-situ hybridisation has 
emerged as an alternative to FISH, since the latter 
requires additional analytic equipment not widely 
available in pathology laboratories (such as dark-field 
fluorescence microscopy and multiband fluorescence 
filters). The CISH test uses a digoxigenin-labelled 
DNA probe (SPPT-Light [Zymed] HER2 CISH kit) to 
HER2 and the hybridised HER2 probe is detected by 
a chromogenic reaction using mouse antidigoxigenin 
antibody, followed by antimouse-peroxidase and 
diaminobenzidine as chromogen. HER2 amplification 
is defined by an average of more than 10 dots or 
large clusters or a mixture of multiple dots and large 
clusters of the HER2 gene per nucleus in more than 
50% of tumour cells. Although CISH has not yet been 
approved by the US FDA, a number of studies have 
shown good (>90 to 100%) concordance between 
CISH and FISH results.14,15
Statistical methods
The Chi squared test was used to test the 
association between HER2 overexpression and other 
clinicopathological characteristics. All statistical tests 
were two-sided and performed at the 0.05 level of 
significance (P value). The Statistical Package for the 
Social Sciences (Windows version 12.0; SPSS Inc, 
Chicago [IL], US) was used for all analyses.
Results
There were 272 consecutive patients with invasive 
breast cancers referred to our department between 
July 2006 and June 2007, who were eligible for review. 
The median age of the patients was 55 (range, 33-92) 
years. Their clinical and pathological characteristics 
are shown in Table 1.
 Of the primary IHC tests, 39%, 21%, and 40% 
were performed in our own laboratory, other public 
hospital laboratories, and private laboratories 
respectively. There were 4 and 19 breast cancers 
reported to be HER2-positive and -negative 
respectively, without detailed IHC scoring. Of the 
249 breast cancers with IHC scoring, the distribution 
for IHC staining of 0, 1+, 2+ and 3+ were 99 (40%), 
40 (16%), 58 (23%), and 52 (21%) respectively. The 
overall HER2 overexpression rate (IHC staining of 3+ 
Characteristic Patients 
No. (%)
Race
Chinese 261 (96)
Other Asians or Caucasians 11 (4)
Reporting pathology laboratories
Our own hospital 105 (39)
Other public hospital 57 (21)
Private/others 110 (40)
Pathological T-classification*
T1 113 (42)
T2 115 (42)
T3 11 (4)
T4 13 (5)
Uncertain 20 (7)
Pathological N-classification*
N0 128 (47)
N1 70 (26)
N2 36 (13)
N3 15 (6)
Uncertain 23 (8)
Group stage*
I 77 (28)
II 116 (43)
III 61 (22)
IV 6 (2)
Uncertain 12 (4)
Histological type
Ductal 248 (91)
Lobular 4 (1)
Others 20 (7)
Histological grade†
Grade 1 42 (15)
Grade 2 121 (44)
Grade 3 68 (25)
Not applicable or missing 41 (15)
Lymphovascular invasion
Positive 87 (32)
Negative 129 (47)
Missing 56 (21)
Hormonal receptor status‡
Positive 212 (78)
Negative 60 (22)
HER2 immunohistochemistry score§
0 99 (40)
1+ 40 (16)
2+ 58 (23)
3+ 52 (21)
TABLE 1. Demographic, clinical, and pathological characteristics 
of the 272 patients with invasive breast cancers
* American Joint Committee on Cancer Staging, 6th edition
† For infiltrating ductal carcinomas only
‡ Tumours with either oestrogen receptor–positive or progesterone 
receptor–positive would be considered as hormonal receptor–
positive
§ For 249 patients with detailed immunohistochemistry (IHC) scores 
only; there were 4 and 19 breast cancers reported to be HER2-
positive and -negative respectively without detailed IHC scoring
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Variable No. of patients HER2 overexpression P value
Positive (%) Negative (%)
Age (years) 0.525
≤45 50 9 (18) 41 (82)
>45 222 49 (22) 173 (78)
T-classification 0.740
T1 113 20 (18) 93 (82)
T2 115 25 (22) 90 (78)
T3-4 24 5 (21) 19 (79)
N-classification 0.691
N0 128 22 (17) 106 (83)
N1 70 15 (21) 55 (79)
N2-3 51 11 (22) 40 (78)
Group staging 0.433
I 77 11 (14) 66 (86)
II 116 25 (22) 91 (78)
III 61 14 (23) 47 (77)
IV 6 2 (33) 4 (67)
Histological grade (ductal carcinoma only) <0.001
1-2 166 21 (13) 145 (87)
3 68 25 (37) 43 (63)
Hormonal receptor status <0.001
Positive 212 34 (16) 178 (84)
Negative 60 24 (40) 36 (60)
TABLE 2. Correlation of HER2 overexpression with clinicopathological characteristics
or reported as positive) was 21%.
 Table 2 shows the association of HER2 
overexpression with common clinicopathological 
characteristics. In our study population, HER2 
overexpression was significantly associated with 
grade 3 histology (for invasive ductal cancer) [P<0.001], 
and negative hormonal receptor status (P<0.001). 
However, there was no association with age (P=0.525), 
T-classification (P=0.740), N-classification (P=0.691), or 
group stages (P=0.433).
 As many patients were reluctant to self-finance 
additional ISH tests, only 37 patients had confirmatory 
ISH tests performed between July 2006 and June 2007. 
Table 3 shows the results of concordance between 
their ISH and IHC tests. Overall, 10 (71%) of 14 
tumours with IHC staining of 3+ and 1 (4%) of 23 with 
IHC staining of 2+ were found to have HER2 gene 
amplification by ISH assays.
Discussion
Although some early studies16,17 reported HER2 
overexpression in as many as 30% of breast cancers, 
more recent findings18,19 suggest the true frequency 
of HER2-positive breast cancer to be only around 15 
to 20%. In our prior study of 902 patients with known 
HER2 status presenting before 2003, we also found a 
relatively high HER2 overexpression rate of 30%.20 It 
was unclear whether this was related to the accuracy 
of HER2 tests in our community setting or due to 
ethnic variation. Moreover, in that study population, 
the adverse impact of HER2 overexpression was only 
evident in patients with four or more positive nodes, 
but not in patients with negative nodes or less than 
four positive nodes.20
IHC score No. of 
patients
ISH tests for HER2 gene
Amplified Non-amplified
3+ (positive) 14* 10 (71%) 4 (29%)
2+ (equivocal) 23† 1 (4%) 22 (96%)
TABLE 3. Degree of concordance between 
immunohistochemistry (IHC) scores and in-situ hybridisation 
(ISH) tests in 37 patients
* All ISH tests for IHC 3+ cases were fluorescence in-situ 
hybridisation (FISH) tests done in the University of Hong Kong
† For IHC 2+ cases, 21 ISH tests were chromogenic in-situ 
hybridisation tests performed in private laboratories and 2 were 
FISH tests done in the University of Hong Kong
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